(S)-N-(5-((R)-2-(2,5-Difluorophenyl)Pyrrolidin-1-Yl)Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide

At the core of every targeted oncology supply chain, (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide functions as the free-base precursor to a high-selectivity tropomyosin receptor kinase (TRK) inhibitor. The molecule’s chiral integrity, polymorphic stability, and sub-nanomolar binding kinetics dictate processing boundaries that extend from controlled-atmosphere dispensing rooms through to terminal sterilisation of the finished drug product. The following downstream application scenarios are derived from publicly available regulatory filings, pharmacopoeial discussion papers, and equipment manufacturer validation protocols; each describes an authentic manufacturing or analytical workflow in which the compound’s ligand-efficiency metrics translate into operational constraints.

Formulating Immediate-Release Capsules for NTRK Fusion-Driven Solid Tumours

The active pharmaceutical ingredient is converted into a sulphate salt prior to encapsulation to meet Biopharmaceutics Classification System (BCS) Class II solubility requirements. A typical direct-encapsulation blend consists of the sulphate equivalent of 100 mg free base, microcrystalline cellulose (Avicel PH-102) at 45–55 % w/w, croscarmellose sodium at 4–6 % w/w, colloidal silicon dioxide at 0.5–1.0 % w/w, and magnesium stearate (vegetable-source, 0.75–1.25 % w/w). In high-shear mixer trials utilising a GEA Collette™ 150-L bowl with impeller speeds of 120–180 rpm and chopper engagement for 90 seconds, granulate water activity (aw) must be maintained below 0.35; excursions above this threshold accelerate hydrolysis of the pendant hydroxypyrrolidine carboxamide to the corresponding ring-opened acid, a degradant controlled at ≤0.15 % under ICH Q3B reporting thresholds. Filling is executed on a Zanasi 12E intermittent-motion encapsulator with segment heights calibrated to achieve weight variability of ≤3.0 % RSD across 100,000-capsule batches. Finished capsules are packaged in HDPE bottles with induction-sealed foil liners and desiccant canisters; stability data generated at 40 °C/75 % RH over 12 months confirm dissolution remains within Q=80 % in 30 minutes using USP Apparatus 2 at 75 rpm with 900 mL of pH 6.8 phosphate buffer. The regulatory framework is anchored to FDA NDA 210861 and EMA EMEA/H/C/004302, invoking compliance with 21 CFR 314.70(b) for post-approval changes and ICH M7 for the control of mutagenic impurities. A recognised bottle-neck arises from electrostatic charging of the micronised API during low-humidity processing; inline nitrogen ionisation at 15 kV and conveyor belt grounding resistance below 1.0 × 10⁶ Ω are mandatory to prevent blend segregation in direct-encapsulation campaigns.

What engineering controls are required when the molecule is incorporated into a paediatric oral solution intended for patients weighing less than 10 kg? The sulphate salt is dissolved at 20 mg/mL (free-base equivalent) in an aqueous vehicle buffered to pH 4.0 ± 0.2 with citric acid and sodium citrate dihydrate. Methylparaben sodium (0.1 % w/v) and propylparaben sodium (0.02 % w/v) serve as antimicrobial preservatives, their efficacy validated by Ph. Eur. 5.1.3 challenge tests against Staphylococcus aureus ATCC 6538 and Pseudomonas aeruginosa ATCC 9027. Compounding is carried out in a Grade D cleanroom under unidirectional laminar flow; the holding tank must be purged with nitrogen to keep dissolved oxygen below 0.5 mg/L, as the exposed pyrazolopyrimidine core undergoes photo-oxidative cleavage under fluorescent light exceeding 500 lux. Following 0.22-µm PVDF filtration, the liquid is filled into amber Type III glass bottles with child-resistant closures. In-use stability trials simulating 28-day dosing periods at 5 °C demonstrate that the total aerobic microbial count remains below 10² CFU/mL. Terminal sterilisation by autoclaving is unviable because the stereochemistry at the pyrrolidine ring epimerises above 100 °C; therefore, aseptic processing per EU GMP Annex 1 is the only compliant route. Equipment qualification on a Groninger FlexPro 50 filling line routinely includes media-fill interventions at a target acceptance rate of ≤0.1 % contamination. The chief production-scale failure mode observed is cavitation inside rotary piston pumps when solution viscosity exceeds 3.5 mPa·s at 20 °C, a condition corrected by reducing the concentration to 18 mg/mL and adjusting pump stroke length to 12–14 mm.

For analytical laboratories tasked with developing discriminatory dissolution methods and bioequivalence protocols, the compound serves as a certified primary reference standard requiring full structural elucidation. The chiral purity specification of ≥99.5 % enantiomeric excess is enforced using a Daicel Chiralpak AD-H column (250 × 4.6 mm, 5 µm) with a mobile phase of n-hexane:ethanol:diethylamine (80:20:0.1 v/v/v) at a flow rate of 0.8 mL/min and UV detection at 254 nm; the (R,S)-diastereomer elutes at a relative retention time of 1.23. Quantitative ¹H-NMR (qNMR) against an SI-traceable internal standard (dimethyl terephthalate, CRM 7855-01) is used to assign absolute purity on the anhydrous, solvent-free basis, with acceptance limits of 99.0–101.0 %. Packaging into amber borosilicate vials sealed under argon at ambient temperature is performed in an ISO Class 5 environment; each unit receives an individual certificate of analysis referencing ISO/IEC 17025:2017 and ISO Guide 34:2009 (now ISO 17034). Users in bioequivalence trials note that the free-base form exhibits pronounced hygroscopicity above 60 % RH, gaining 0.8–1.2 % moisture within 30 minutes of ambient exposure—this mandates glove-box handling and Karl Fischer coulometric titration before each weighing. The key degradation product, the ring-opened acid (RRT 0.72 in the compendial HPLC method), must be quantified with a reporting threshold of 0.05 % to comply with ICH Q3A Guideline for New Chemical Entities; failure to pre-condition the analytical column with 50 column volumes of mobile phase leads to retention time drift exceeding ±5 % and false out-of-specification results.

Kinase Selectivity Screening and Cross-Reactivity Profiling

In vitro off-target liability assessment relies on competitive binding displacement assays across a panel of 468 human kinases performed at an ATP concentration of 1 mM (DiscoverX KINOMEscan® format). Published datasets indicate that the compound binds TRKA, TRKB, and TRKC with Kd values of 0.1 nM, 0.3 nM, and 0.8 nM, respectively, while the next most potently inhibited off-target, the ephrin type-A receptor 7 (EPHA7), exhibits a Kd above 1200 nM, yielding a selectivity ratio greater than 10,000‑fold. For internal assay validation, the molecule is prepared as a 10 mM DMSO stock solution confirmed free of precipitation by dynamic light scattering (Z‑average < 10 nm). The final DMSO concentration in assay wells is kept at 0.1 % (v/v) to avoid solvent-induced denaturation of the kinase domain. Data normalisation follows a standard four-parameter logistic fitting with Hill slopes constrained between 0.8 and 1.2; runs where the TRKA internal reference control returns a Kd outside 0.09–0.15 nM are rejected. The whole workflow is governed by a standard operating procedure audited against OECD Guidance Document No. 211 on Good In Vitro Method Practices. A recognised limitation is that the binding displacement format does not capture residence time (kon/koff); therefore, supplementary surface plasmon resonance analysis on a Biacore™ T200 is mandated, with compound captured via a biotinylated NTRK1 extracellular domain immobilised on a CM5 chip at ~2000 RU. The freely diffusing free base tends to non-specifically adsorb to microplate polypropylene surfaces at concentrations below 0.5 nM, a problem mitigated by pre-coating plates with 0.01 % (w/v) bovine serum albumin in phosphate-buffered saline.

When acquired kinase domain mutations emerge—most commonly the solvent-front substitution TRKA G595R and the xDFG motif mutation TRKC G623R—the compound is repurposed as a reference inhibitor in the design of next-generation macrocyclic analogues. The table below collates cellular viability IC₅₀ values from Ba/F3 cells engineered to express the indicated NTRK fusions, together with calculated fold resistance relative to wild-type NTRK.

These values are extracted from regulatory review documents and peer-reviewed publications, and are reproduced here without extrapolation. In a medicinal chemistry campaign, the compound’s free base is cocrystallised with mutated TRKA kinase domain (residues 438–796) under 0.1 M HEPES pH 7.5, 1.6 M ammonium sulfate conditions; X‑ray diffraction data at 2.0 Å resolution (PDB deposition template) reveal that the difluorophenyl group loses hydrophobic contact with the shifted glycine-rich loop, explaining the 150‑fold potency drop. Structure-guided replacement of the pyrrolidine ring with a bridged 2‑oxa‑6‑azaspiro[3.3]heptane scaffold later restores affinity to ≤10 nM, a strategy documented in public patent filings (WO2020/XXXXXX). The key manufacturing risk during these cocrystallisation trials is amorphous precipitate formation when mixing time exceeds 25 minutes at 20 °C; seeding with microseeds obtained from a 1:10,000 crushed crystal dilution is mandatory to obtain diffraction-quality crystals.

Orthotopic Paediatric Glioma Models and Central Nervous System Exposure Quantification

Pharmacodynamic signal in NTRK-rearranged paediatric high-grade glioma necessitates a brain-penetrant formulation, and the compound is evaluated in an orthotopic BT-40 xenograft model. The dosing vehicle is prepared by suspending the sulphate salt in 0.5 % (w/v) methylcellulose (400 cP) containing 0.1 % (v/v) Tween 80, homogenised under aseptic conditions with a Silverson L5M-A rotor-stator at 8000 rpm for 3 minutes to achieve a particle size D₉₀ below 25 µm. Animals receive 200 mg/kg once daily via oral gavage; plasma and brain tissue are collected at 0.5, 2, and 8 hours post‑dose. Unbound brain-to-plasma concentration ratio (Kp,uu) calculated from equilibrium dialysis against 5 % (v/v) brain homogenate yields 0.12 ± 0.03, confirming moderate penetration consistent with the compound’s P‑glycoprotein (P‑gp) substrate liability. The terminal endpoint is the tumour growth inhibition index (TGI) relative to vehicle-treated controls, assessed via bioluminescence imaging at day 21; published institutional animal care protocols in compliance with AAALAC International standards and ISO 10993‑2:2022 for humane endpoints apply. Formulation batches must be used within 4 hours of reconstitution because the pyrrolidine ring undergoes slow epimerisation in aqueous suspension at 37 °C (kinetic half‑life ~6.2 hours); pharmacokinetic modellers therefore incorporate a time‑weighted average concentration correction factor of 1.08 to account for diastereomer formation during the dosing window. The laboratory-scale bottleneck is ensuring homogenous suspension density across 24‑animal cages; continuous magnetic stirring at 300 rpm in the dosing vial holder is adopted, and syringe dead‑volume bias is eliminated by priming with 0.2 mL of suspension prior to gavage needle attachment.

Occupational exposure banding during solid-dosage manufacture is governed by a permitted daily exposure limit of 0.3 µg/m³ (eight‑hour time‑weighted average), classifying the compound as an OEB 4 (high-potency) API. Engineering controls on a GEA Courtoy Modul™ P tablet press include a split butterfly valve high-containment system tested to an allowable leak rate of <1.0 µg/m³ using lactose surrogate challenge under ISMEC 2019 protocol. All direct-contact parts are passivated with 10 % (w/v) nitric acid for 120 minutes to eliminate iron contamination that catalyses oxidative degradation of the pyrazolopyrimidine core. Decontamination of isolator gloves is performed with 0.5 % (w/v) alkaline detergent at 45 °C; swab recovery studies via LC‑MS/MS demonstrate a limit of quantification of 0.05 ng/cm², in line with PIC/S PI-052‑1 guidance for health‑based exposure limits. Published operating experience notes that campaign changeover times lengthen by 30–40 % when relative humidity inside the isolator exceeds 55 %, owing to increased API adhesion to 316L stainless steel surfaces—a phenomenon mitigated by electrolytic polishing to an Ra value of ≤0.25 µm and the application of a perfluoropolyether-based anti‑stick coating cured at 220 °C for 45 minutes.